| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
S87135-5mg促销 |
≥98% | ￥738.00 ￥664.00 |
6 | - | - | - | - |
|
S87135-10mg促销 |
≥98% | ￥1030.00 ￥929.00 |
7 | - | - | - | - |
|
S87135-25mg促销 |
≥98% | ￥2500.00 ￥2250.00 |
3 | - | - | - | - |
|
S87135-50mg促销 |
≥98% | ￥4100.00 ￥3690.00 |
1 | - | - | - | - |
|
S87135-100mg促销 |
≥98% | ￥6010.00 ￥5410.00 |
2 | - | - | - | - |
|
S87135-250mg促销 |
≥98% | ￥12000.00 ￥10800.00 |
1 | - | - | - | - |
|
| 产品描述： | XL228 is a multi-targeted tyrosine kinase inhibitor with IC50s of 5, 3.1, 1.6, 6.1, 2 nM for Bcr-Abl, Aurora A, IGF-1R, Src and Lyn, respectively. | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点： | Aurora A:3.1 nM (IC50);IGF-1R:1.6 nM (IC50);IGF-1R;Bcr-Abl;Src;AuroraKinase | ||||||||||||||||||||
| 体内研究： | Single-dose pharmacodynamics studies demonstrate a potent effect of XL228 on BCR-ABL signaling in K562 xenograft tumors. Phosphorylation of BCR-ABL is decreased by 50% at XL228 plasma concentrations of 3.5 μM; a similar decrease in phospho-STAT5 occurred at 0.8 μM plasma concentration | ||||||||||||||||||||
| 参考文献： | 1. Cortes J, et al. Preliminary Clinical Activity in a Phase I Trial of the BCR-ABL/IGF- 1R/Aurora Kinase Inhibitor XL228 in Patients with Ph++ Leukemias with Either Failure to Multiple TKI Therapies or with T315I Mutation. Blood 2008 112:3232 2. Douglas O, et al. Abstract C192: Characterization of the target profile of XL228, a multi‐targeted protein kinase inhibitor in phase 1 clinical development. Mol Cancer Ther 2009;8(12 Suppl):C192. 3. Shah N, et al. Targeting Drug-Resistant CML and Ph+-ALL with the Spectrum Selective Protein Kinase Inhibitor XL228. Blood 2007 110:474; | ||||||||||||||||||||
| 溶解性： | Soluble in DMSO | ||||||||||||||||||||
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京